Abstract
Copper catalyzed azide-alkyne cycloaddition (CuAAC) chemistry is reported for the construction of previously unknown 5-(1H-1,2,3-triazol-1-yl)-4,5′- bithiazoles from 2-bromo-1-(thiazol-5-yl)ethanones. These novel triazolobithiazoles are shown to have cystic fibrosis (CF) corrector activity and, compared to the benchmark bithiazole CF corrector corr-4a, improved log P values (4.5 vs 5.96).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 5247-5253 |
| Number of pages | 7 |
| Journal | Bioorganic and Medicinal Chemistry |
| Volume | 20 |
| Issue number | 17 |
| DOIs | |
| State | Published - Sep 1 2012 |
Keywords
- CF corrector
- CuAAC
- Cystic fibrosis
- Triazolobithiazole
ASJC Scopus subject areas
- Pharmaceutical Science
- Drug Discovery
- Organic Chemistry
- Molecular Medicine
- Molecular Biology
- Clinical Biochemistry
- Biochemistry
Fingerprint Dive into the research topics of 'Click-based synthesis of triazolobithiazole Δf508-CFTR correctors for cystic fibrosis'. Together they form a unique fingerprint.
Cite this
Donald, M. B., Rodriguez, K. X., Shay, H., Phuan, P. W., Verkman, A. S., & Kurth, M. J. (2012). Click-based synthesis of triazolobithiazole Δf508-CFTR correctors for cystic fibrosis. Bioorganic and Medicinal Chemistry, 20(17), 5247-5253. https://doi.org/10.1016/j.bmc.2012.06.046